CESCA Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

RANCHO CORDOVA, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. KOOL, a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Jeffery Cauble, principal accounting officer, will present at the Rodman & Renshaw 19^th Annual Global Investment Conference on Tuesday, September 12, 2017 at 8:20am ET. The conference is being held September 10-12 at the Lotte New York Palace Hotel in New York City. 

A live webcast of the presentation will be available on the Events and Presentations page of the company's website: www.cescatherapeutics.com. The webcast will be archived for 90 days.

About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.

Forward-Looking Statement

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics' annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

Company Contact: 
Cesca Therapeutics Inc. 
Wendy Samford
916-858-5191
ir@cescatherapeutics.com

Investor Contact: 
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com